Results 281 to 290 of about 3,067,072 (318)

JAK Inhibitors for Myelofibrosis: Strengths and Limitations

Current Hematologic Malignancy Reports
The landscape of myelofibrosis (MF) has changed since the discovery of the JAK2 V617F mutation and subsequent development of JAK inhibitors (JAKis). However, treatment with JAKis remain a challenge.
K. Thaw, C. Harrison, P. Sriskandarajah
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

JAK Inhibitor in CALR-Mutant Myelofibrosis

New England Journal of Medicine, 2014
na
PASSAMONTI, FRANCESCO, Caramazza, D., Maffioli, M.   +2 more
openaire   +6 more sources

JAK inhibitors in dermatology

Indian Journal of Skin Allergy, 2023
The four Janus Kinase (JAK) proteins and seven signal transducer and activator of transcription (STAT) factors mediate the intracellular signaling pathway of cytokine receptors, which are described in the pathogenesis of many autoimmune, allergic, and inflammatory dermatoses.
S. K. Shahriar Ahmed, Abhishek De, Aarti Sarda, Kiran Godse, Sandipan Dhar   +4 more
openaire   +1 more source

JAK inhibitors for the treatment of vitiligo

Journal of Dermatological Science
Vitiligo is an autoimmune disease involving melanocyte-targeting T cells initiated by environmental and genetic factors. Steroids and tacrolimus have been used as topical treatments. Recently, novel topical agents targeting Janus kinase (JAK), a family of tyrosine kinases that regulates cytokine signaling, have emerged.
Shintaro, Inoue, Tamio, Suzuki, Shigetoshi, Sano, Ichiro, Katayama   +3 more
openaire   +2 more sources

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.

Pharmacological Research, 2022
The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK homology pseudokinase (JH2) domain that interacts with and regulates the activity of ...
R. Roskoski
semanticscholar   +1 more source

JAK Inhibitors in Solid Organ Transplantation

The Journal of Clinical Pharmacology, 2023
AbstractJanus kinase (JAK) inhibitors are a novel group of immunosuppressive drugs approved to treat certain rheumatic and allergic disorders; however, their efficacy in the regulation of alloimmune responses after solid organ transplantation has not yet been elucidated.
Sara Assadiasl, Hanieh Mojtahedi, Mohammad Hossein Nicknam   +2 more
openaire   +2 more sources

Cardiovascular safety, cancer and Jak-inhibitors: differences to be highlighted.

Pharmacological Research, 2022
Rheumatoid arthritis (RA) is a chronic inflammatory disease whose natural history leads to articular and extra-articular damage. Both cardiovascular risk and malignancy risk results higher in RA patients, compared to general population.
M. Benucci, A. Damiani, M. Infantino, M. Manfredi, B. Lari, V. Grossi, F. Gobbi, P. Sarzi-Puttini   +7 more
semanticscholar   +1 more source

JAK Protein Kinase Inhibitors

Drug News & Perspectives, 2005
In humans, the Janus protein tyrosine kinase family (JAKs) contains four members: JAK1, JAK2, JAK3 and TYK2. JAKs phosphorylate signal transducers and activators of transcription (STATs) simultaneously with other phosphorylations required for activation, and there are several cellular mechanisms in place to inhibit JAK/STAT signaling. That one might be
openaire   +2 more sources

JAK‐inhibitors in dermatology – small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2021
Numerous chronic inflammatory skin diseases are associated with the release of proinflammatory cytokines, which act via the intracellular JAK‐STAT pathway.
Benjamin Klein, R. Treudler, J. Simon
semanticscholar   +1 more source

[JAK inhibitor].

Nihon rinsho. Japanese journal of clinical medicine, 2013
Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment ...
Kunihiro, Yamaoka, Yoshiya, Tanaka
openaire   +1 more source